Research programme: cartilage growth factor receptors - RegeneronAlternative Names: Cartilage growth factor receptors research programme - Regeneron
Latest Information Update: 28 Jun 2006
At a glance
- Originator Regeneron Pharmaceuticals
- Mechanism of Action Intercellular signalling peptide and protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 11 Jul 2000 New profile
- 11 Jul 2000 Preclinical development for Osteoarthritis in USA (Unknown route)